Just Answers - Finance

After 28 years as a financial services coach probably the single biggest dilemma I have seen facing investors is when do I sell? How do I kn

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ow if I should sell this stock? The old expression holds true: it's easy to buy, but really hard to sell.

Selling a stock is sometimes the

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

quivalent of parting with a loved one. What if I just hold on, it might go a bit higher; or, the stock is down, you are disappointed and eve

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

n angry. That discussion ranges from "I should have known better" to " you've disappointed me so much". A sociologist client of mine once to

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

d me that scolding a down stock is like addressing a juvenile delinquent. Same painful language.

So what do we do? Many professional portfo

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

lio managers will not buy a stock until they have determined in their minds a strict price target for selling it. Seems simple enough, but t

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

e art of investing is sticking to it.Emotions do enter the picture.

By sticking to it I mean that as the stock approaches your price target

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

; it is time to have a frank conversation with your broker/advisor. You have to pretend you do not own it. Would I be a buyer here at this n

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

w higher price if I didn't own a share? Have the underlying fundamentals of the company (stock) or the industry in which it competes changed

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

at all? Is the growth rate intact, or accelerating? Has the senior management given any indication that their publicly stated goals for rev

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

nues and earnings changed at all?

These are the hard questions that must be honestly asked, and more importantly, honestly answered. What y

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

u'll learn is that it's okay to keep the stock and raise your price target to higher levels. If the answers to the questions are lukewarm, t

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

hen sell...and do not look back.

I had a British portfolio manager client that managed a multi-billion dollar US stock growth fund who rais

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

d his price target on Cisco Systems 33 times before he ever sold one share. The key to his success was to re-validate the reasons and the fu

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ndamentals of his stock over and over again. It is a refreshing process as you eliminate all your emotions from a stock story and as Joe Fri

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ay would say " just the facts, please".

The opposite action is also imperative if you wish to succeed as an investor. What is my downside p

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

rotection price? If you buy a stock at $20, and it is now trading at $17, re-ask all the same questions all over again. Is it just a sloppy

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

arket? Are the fundamentals intact? Is senior management backing away from revenue and earnings projections? Has the growth rate begun to sl

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ow down? Would I be a buyer here if I did not own any shares? You get the idea.

Amazing things happen to the overall performance of a portf

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

lio when strict price targets are established, both for the upside and the downside. Your losses are minimized and your profits are maximize

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justanswers.org.ua/article/102688/justanswers-Stop-Losing-Money-TodayReady-AimTarget.html">Stop Losing Money Today--Ready, Aim...Target</a>

BB link (for phorums):
[url=http://www.justanswers.org.ua/article/102688/justanswers-Stop-Losing-Money-TodayReady-AimTarget.html]Stop Losing Money Today--Ready, Aim...Target[/url]

“Blame your parents when you have no food and blame the government when your business is bad.” Such wrong attitude provides a bad start to solving your problems. Shame and blame are not justifiable. Take responsibility.

Site content would have to be one of the most important aspects of your marketing efforts, inducing a customer to purchase and also do repeat business.

Tags

Links

Just Answers - Stop Losing Money Today--Ready, Aim...Target

Related Articles: